Cardio Diagnostics (CDIO)

• Market cap: $5.48M
• 1 day: -1.07%
• 5 days: -8.87%
• 1 month: 18.59%
• 3 months: 2.78%
• 6 months: -64.42%
• Year to date: -34.86%
• 1 year: -51.19%
• 5 years: -99.37%
• 10 years: -99.37%
• Sector: Healthcare
• Industry: Biotechnology

About: Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.

Employees: 17